Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Standard of care for treatment of nasopharyngeal carcinoma is chemoradiation with concurrent
cisplatin. Addition of a second agent, cetuximab, which targets nasopharyngeal carcinoma
cells with high EGFR protein expression, may enhance the effectiveness of radiation and
result in better tumour control. This study investigates the addition of 2 cycles of
cisplatin/5FU chemotherapy with cetuximab, followed by cisplatin and cetuximab concurrent
with radiation, for treatment of locally advanced nasopharyngeal carcinoma.